Sort   by:  
 Page size 
ModelsGonzalez2021 - QSAR Prediction Model for CYP3A4 Inhibitor and Substrate
Analysis of metabolic stability, determining the inhibition of CYP3A4 activity and whether the compounds are a substrate for the CYP3A4 enzyme. The data used to build these models has been publicly available at PubChem (AID1645841) by ADME@NCATS. Model Type: Predictive machine learning model. Model...
2024-05-10 | MODEL2404160001 | BioModels
Machine Learning Model Ersilia 
GenomicsTo understand the effects of global Cyp27a1 and Cyp3a4 gene deletions on bile acid synthesis
To understand the effects of global Cyp27a1 and Cyp3a4 gene deletions on bile acid synthesis
PRJNA610812 | ENA
UnknownCYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing.
Not available
S-EPMC4674354 | biostudies-literature
GenomicsCYP3A4-mediated metabolic variability drives resistance and systemic toxicities under targeted therapies for non–small cell lung cancer
CYP3A4-mediated metabolic variability drives resistance and systemic toxicities under targeted therapies for non–small cell lung cancer
PRJNA1491135 | ENA
TranscriptomicsThe non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs
Vault particles are conserved organelles that have been implicated in multidrug resistance and intracellular transport. They are formed by three different proteins and the non-coding vault RNAs (vRNAs). Here we show that human vRNAs produce several small RNAs (svRNAs) by mechanisms different from th...
ORGANISM(S): Homo sapiens 
2009-09-07 | E-GEOD-16060 | biostudies-arrayexpress
GenomicsImpact of plastic-related compounds on the gene expression signature of HepG2 cells transfected with CYP3A4
Impact of plastic-related compounds on the gene expression signature of HepG2 cells transfected with CYP3A4
PRJNA996522 | ENA
UnknownAlflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer.
Not available
S-EPMC7608132 | biostudies-literature
TranscriptomicsCYP3A4-mediated metabolic variability drives resistance and systemic toxicities under targeted therapies for non–small cell lung cancer
Targeted therapies, including small molecule inhibitors of mutant ALK, EGFR, and RAS in lung cancers, can produce strong and durable clinical responses, yet a subset of tumors fail to respond, and even strong responders eventually relapse. Further, although targeted therapies are typically well tole...
ORGANISM(S): Mus musculus 
2026-07-13 | GSE337809 | GEO
ProteomicsFunctional effects of CYP3A-CYP2E1 interactions and their role in activation of CYP3A enzymes by chronic alcohol exposure
Aiming to examine the effect of chronic alcohol exposure on the activity of CYP3A enzymes in human liver, we studied the metabolism of two CYP3A-specific substrates, 7-benzyloxyquinoline (7-BQ) and ivermectin, in 23 preparations of human liver microsomes (HLM) obtained from donors with documented al...
ORGANISM(S): Homo sapiens (Human) 
2026-09-18 | PXD079247 | Pride
Cytochrome p450  cyp2e1  cyp3a4  cyp3a5  nadph-cytochrome p450 reductase  pro-tein-protein interactions  7-benzyloxyquinoline  ivermectin  human liver microsomes  alcohol consumption  alcohol-drug interactions  cross-linking mass spectrometry 
UnknownLigand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection.
Not available
S-EPMC2683693 | biostudies-literature
Sort   by:  
 Page size